In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control
SOURCE CITATION: Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271-281. 38071986.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:177 |
|---|---|
| Enthalten in: |
Annals of internal medicine - 177(2024), 4 vom: 16. Apr., Seite JC43 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stanbrook, Matthew B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
71492GE1FX |
|---|
| Anmerkungen: |
Date Completed 17.04.2024 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.7326/J24-0014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370504054 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370504054 | ||
| 003 | DE-627 | ||
| 005 | 20240417232829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240403s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7326/J24-0014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM370504054 | ||
| 035 | |a (NLM)38560905 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stanbrook, Matthew B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In severe eosinophilic asthma controlled with benralizumab, tapering high-dose ICS reduced dose while maintaining control |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2024 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SOURCE CITATION: Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271-281. 38071986 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a benralizumab |2 NLM | |
| 650 | 7 | |a 71492GE1FX |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of internal medicine |d 1945 |g 177(2024), 4 vom: 16. Apr., Seite JC43 |w (DE-627)NLM000012777 |x 1539-3704 |7 nnns |
| 773 | 1 | 8 | |g volume:177 |g year:2024 |g number:4 |g day:16 |g month:04 |g pages:JC43 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7326/J24-0014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 177 |j 2024 |e 4 |b 16 |c 04 |h JC43 | ||